Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Akoya (NASDAQ: AKYA) for possible breaches of fiduciary duty and other violations of law in its transaction with Quanterix.

Click here to learn how to join our investigation and obtain additional information or contact us at [e-mail] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Akoya stockholders will receive only 0.318 shares of Quanterix common stock for each share of Akoya common stock owned. Akoya insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Akoya by imposing a significant penalty if Akoya accepts a competing bid. We are investigating the conduct of Akoya’ board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.